Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML
<br /> Farhad Ravandi-Kashani, MD, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia.
Farhad Ravandi-Kashani, MD, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia (AML).
According to Ravandi-Kashani, all patients with AML have expression of CD33, so it is almost a universally present target. In acute lymphoblastic leukemia, an anti-CD33 bi-specific T-cell engager (BiTE), such as blinatumomab (Blincyto), has been useful for the relapsed/refractory population, as well as in those with measurable minimal residual disease (MRD).
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
